Jubilant Ingrevia consolidated Q1 FY2024 PAT up QoQ at Rs. 57.59 Cr
Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023
Jubilant Ingrevia has reported total income of Rs. 1083.52 crores during the period ended June 30, 2023
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
Health-tech startups have the potential to revolutionize the healthcare sector by supporting innovations
Aurobindo will respond to the US FDA within the stipulated timelines
This product would be manufactured at Lupin's Nagpur facility in India
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
The maker of ivermectin/pyrantel, the #1 vet-recommended and #1 dog-preferred real beef chew introduces the latest innovation in its portfolio
Luforbec® 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Subscribe To Our Newsletter & Stay Updated